Reports

CMS Energy announced first quarter 2025 earnings per share of $1.01, with adjusted earnings per share of $1.02. The company reaffirmed its 2025 adjusted earnings guidance of $3.54 to $3.60 per share and long-term adjusted EPS growth of 6 to 8 percent, expressing continued confidence toward the high end.

• Reported earnings per share for Q1 2025 were $1.01, up from $0.96 in Q1 2024.
• Adjusted earnings per share for Q1 2025 were $1.02, up from $0.97 in Q1 2024.

Tenet Healthcare Corporation announced strong first quarter 2025 results, with net income available to common shareholders at $406 million and adjusted diluted earnings per share increasing by 35.4% to $4.36. Consolidated Adjusted EBITDA rose 13.6% to $1.163 billion, driven by strong same-hospital admissions and ambulatory net revenue per case.

• Net income available to common shareholders in Q1 2025 was $406 million, or $4.27 per diluted share.
• Adjusted diluted earnings per share increased 35.4% to $4.36 in Q1 2025 compared to $3.22 in Q1 2024.

Frontier Communications reported strong first-quarter 2025 results, driven by significant growth in its fiber business. The company saw a 19% increase in fiber broadband customers and a 24% growth in fiber broadband revenues, leading to record first-quarter revenue and Adjusted EBITDA. Frontier also expanded its fiber network to over 8 million passings.

• Total revenue for Q1 2025 was $1,511 million, up from $1,462 million in the prior year quarter.
• Net loss for Q1 2025 was $64 million, compared to net income of $1 million in the prior year quarter.

Glaukos reported a strong start to 2025 with record net sales of $106.7 million in the first quarter, representing a 25% increase year-over-year. The company's operating loss improved significantly to $20.7 million from $39.1 million in the same period last year. Glaucoma sales were a key driver of growth, increasing 31% year-over-year.

• Record net sales of $106.7 million in Q1 2025, up 25% year-over-year.
• Glaucoma net sales reached a record $88.1 million, a 31% increase from the prior year.

Loar Holdings Inc. delivered $110.4 million in revenue during Q4 2024, representing a 27.8% increase year-over-year. Net income reached $3.7 million, reversing a net loss from the same quarter in 2023. Adjusted EPS came in at $0.11, supported by robust performance across key end-markets and operational efficiencies.

• Q4 2024 revenue rose 27.8% YoY to $110.4 million.
• Net income reached $3.7 million, reversing a $0.6 million loss in Q4 2023.

Dun & Bradstreet reported a solid start to 2025 with organic revenue growth of 3.6% and an increase in Adjusted EBITDA margin. Both North America and International segments showed strong demand in Finance & Risk and Sales & Marketing solutions. The company also improved its net leverage ratio.

• Revenue for Q1 2025 was $579.8 million, a 2.7% increase year-over-year.
• GAAP net loss was $15.8 million, or $0.04 per share.

JFrog reported strong first-quarter 2025 results, exceeding expectations, with significant growth in revenue, driven by cloud adoption and platform expansion, and improved non-GAAP profitability, while maintaining a cautious outlook amidst macroeconomic uncertainty.

• Total subscription revenue for Q1 2025 was $122.4 million, a 22% increase year-over-year.
• Non-GAAP net income for Q1 2025 was $23.3 million, resulting in non-GAAP diluted EPS of $0.20.

Valaris reported a net loss of $39 million in the first quarter of 2025, primarily due to a significant discrete tax expense of $167 million. Despite the loss, total operating revenues increased to $621 million, and operating income rose to $143 million, driven by stronger performance in the floater segment. The company also achieved a revenue efficiency of 96% and secured approximately $1.0 billion in new contract backlog, increasing the total backlog to over $4.2 billion.

• Reported a net loss of $39 million, impacted by $167 million of discrete tax expense.
• Total operating revenues increased 6% to $621 million compared to the previous quarter.

Progress Software reported Q1 2025 revenue of $238 million, reflecting a 29% year-over-year increase. Non-GAAP EPS rose to $1.31, while net income declined due to acquisition-related and restructuring costs. Strong ARR growth, controlled expenses, and continued integration of ShareFile supported performance.

• Revenue rose 29% YoY to $238 million, boosted by product strength and ShareFile contribution.
• Non-GAAP EPS increased 5% to $1.31, while GAAP EPS declined 53% to $0.24.

FIGS exceeded expectations in the first quarter of 2025, driven by customer growth, strong full-priced sales, and a record average order value. The company saw a return to growth in the U.S. market. However, changes in U.S. trade policies have introduced variability to the full-year outlook, leading to an updated forecast reflecting the projected impact of the current tariff structure.

• Net revenues grew by 4.7% year-over-year in the first quarter of 2025.
• The company reported a net loss of $102,000 for the quarter.

In Q4 2024, Microvast achieved record quarterly revenue of $113.4 million, marking an 8.4% year-over-year increase. The company significantly improved its gross margin to 36.6% and reduced its non-GAAP adjusted net loss to $0.6 million. While GAAP net loss stood at $82.3 million, operational efficiency gains and restructuring helped generate positive cash from operations.

• Quarterly revenue reached a record $113.4 million, up 8.4% YoY.
• GAAP gross margin improved to 36.6% from 22.0% in Q4 2023.

In Q4 2024, Open Lending experienced a dramatic swing to negative revenue and a substantial net loss due to a downward adjustment in estimated profit share revenues. Despite stable program fees and a consistent number of certified loans, macroeconomic challenges and vintage underperformance severely impacted financials.

• Total revenue dropped to -$56.9 million due to an $81.3 million negative adjustment in profit share revenue.
• Net loss widened to $144.4 million from $4.8 million in Q4 2023.

Omeros Corporation reported a net loss of $31.4 million for the fourth quarter of 2024, an improvement from the $32.2 million net loss in the previous quarter. The company's cash and short-term investments decreased significantly from the prior year, reflecting substantial cost outlays. Key developments include the resubmission of the BLA for narsoplimab and the initiation of a Phase 3 program for zaltenibart.

• Net loss for Q4 2024 was $31.4 million, or $0.54 per share, an improvement from Q3 2024.
• Cash and short-term investments decreased by $81.7 million from December 31, 2023, totaling $90.1 million.

Spire Global generated $21.66 million in revenue during Q4 2024, reflecting progress in customer acquisition and contract renewals. Although the company reported a net loss, both GAAP and Non-GAAP EPS improved year-over-year. ARR guidance suggests continued strength heading into 2025.

• Q4 2024 revenue was $21.66 million, up from $20.4 million in Q4 2023.
• GAAP EPS improved to -$0.73 from -$1.23 a year earlier.

Nanox generated $3.0 million in revenue for Q4 2024, up from $2.4 million in the prior year period. Despite revenue growth, the company posted a net loss of $14.1 million and an operating loss of $15.0 million. The non-GAAP EPS stood at -$0.17. Teleradiology services accounted for most of the revenue.

• Generated $3.0 million in Q4 revenue, up from $2.4 million YoY.
• Posted a net loss of $14.1 million and an operating loss of $15.0 million.

Celcuity's fourth quarter results reflected a significant rise in R&D and administrative expenses, contributing to a wider net loss. However, the company ended the quarter with a strong cash position to support ongoing clinical development programs.

• Q4 2024 net loss widened to $36.7 million compared to $18.8 million in Q4 2023.
• Non-GAAP adjusted net loss was $32.3 million, or $0.75 per share.

Rekor Systems achieved $13.28 million in revenue in Q4 2024, reflecting a 20% increase year-over-year. The company improved its adjusted EBITDA and gross margin, and reported an adjusted EPS of -$0.22. Operational progress included enhanced deployment of its AI-driven traffic management platform.

• Q4 2024 revenue reached a record $13.28 million, up 20% year-over-year.
• Adjusted EPS improved to -$0.22 in Q4 2024.

Babcock & Wilcox posted Q4 2024 revenue of $200.8 million, a 15% increase year-over-year, alongside a narrowed net loss and positive operating income. Adjusted EBITDA climbed to $23.9 million as core operations performed strongly, particularly in the Thermal segment. However, substantial interest expenses and continued development costs for strategic projects contributed to a $45 million net loss.

• Revenue grew to $200.8 million, up 15% YoY.
• Adjusted EBITDA increased to $23.9 million from $15.4 million.

Wrap Technologies, Inc. announced strong financial results for Q4 2024, with revenue increasing by 47% to $0.9 million and gross profit improving significantly from a loss to a gain. The company also saw a substantial decrease in total operating expenses and a marked improvement in net loss from operations, indicating successful restructuring efforts.

• Q4 2024 revenue increased by 47% year-over-year, from $0.6 million in 2023 to $0.9 million in 2024.
• Gross Profit improved by $0.7 million in Q4 2024, rising from $(0.3) million in 2023 to $0.4 million in 2024.

Lazydays faced a challenging fourth quarter in 2024, with a notable decline in revenue and deepening losses, including impairment charges and a loss from changes in warrant liability values.

• Q4 revenue declined to $159.9 million from $198.0 million YoY.
• Net loss narrowed slightly to $96.1 million from $108.0 million in Q4 2023.

Tonix Pharmaceuticals reported a net loss of $22.1 million for Q4 2024, with product revenue of $2.6 million. The company's cash and cash equivalents stood at $98.8 million as of December 31, 2024, and it expects to have sufficient cash to fund operations beyond the FDA PDUFA goal date for TNX-102 SL.

• TNX-102 SL for fibromyalgia has an FDA PDUFA goal date of August 15, 2025, and is expected to launch in Q4 2025 if approved.
• The company reported positive topline results from a Phase 1 study of TNX-1500 for kidney transplant rejection and autoimmune diseases.

In Q4 2024, ESS Tech generated $2.85 million in total revenue, including $49,000 from related parties. The company reported a significant gross loss of $13.19 million due to high production costs and ended the quarter with a net loss of $23.48 million. Despite the losses, ESS achieved breakeven profitability on its latest Energy Center design and announced its next-generation Energy Base product.

• Q4 revenue totaled $2.85 million, with $49,000 from related parties.
• Gross loss widened to $13.19 million due to $16 million in cost of revenue.

Curis, Inc. reported a net loss of $9.6 million for the fourth quarter of 2024, an improvement from a net loss of $11.7 million in the same period last year. Revenues for the quarter were $3.3 million, up from $2.7 million in Q4 2023. The company also announced positive clinical data for emavusertib in TakeAim Lymphoma and Leukemia studies, and secured Orphan Drug Designation for PCNSL in both the US and EU.

• Curis successfully concluded meetings with the FDA and EMA regarding a potential accelerated approval path for emavusertib in PCNSL.
• Emavusertib received Orphan Drug Designation for PCNSL in both the US and Europe.

In Q4 2024, Workhorse posted a net loss of $21.2 million on $2.0 million in revenue. Cost reduction efforts and deliveries under new contracts like FedEx helped soften the quarterly loss.

• Secured GSA contract and began shipments under the FedEx Master Agreement.
• Delivered 15 W56 trucks to FedEx and received 7 additional orders.

In Q4 2024, Talphera (formerly AcelRx) reported no revenue, reflecting the transition in its commercial strategy. The company significantly reduced its operating expenses to $3.0 million, down from $4.6 million a year earlier. As a result, the net loss narrowed to $1.87 million, compared to $4.52 million in Q4 2023. Cash and investments stood at $8.86 million at quarter end.

• No revenue was recognized in Q4 2024, down from $281,000 in Q4 2023.
• Operating expenses decreased to $3.0 million, reflecting cost reductions.

LM Funding achieved net income of $2.0 million in Q4 2024, a strong turnaround from a $1.6 million loss in Q4 2023. The company generated $2.0 million in revenue mainly from Bitcoin mining and improved operational efficiency, resulting in Core EBITDA of $3.3 million.

• Generated $2.0 million in total revenue for Q4 2024.
• Achieved net income of $2.0 million compared to a $1.6 million loss in Q4 2023.

Precipio, Inc. reported positive Adjusted EBITDA of $0.4 million and a positive cash flow increase of $0.3 million in Q4 2024, indicating a significant step towards financial independence and profitability.

• Achieved positive Adjusted EBITDA of $0.4 million for Q4 2024.
• Reported a positive cash flow increase of $0.3 million in Q4 2024.

Bionano Genomics reported a total revenue of $8.2 million for the fourth quarter of 2024, a 24% decrease compared to Q4 2023, primarily due to the discontinuation of clinical services. However, GAAP gross margin significantly improved to 42% from 23% in the prior year. The company also achieved substantial reductions in operating expenses, decreasing them to $15.4 million from $27.4 million in Q4 2023.

• Total revenue for Q4 2024 was $8.2 million, a 24% decrease from Q4 2023, mainly due to the absence of revenue from discontinued clinical services.
• GAAP gross margin for Q4 2024 significantly increased to 42% from 23% in Q4 2023, indicating improved profitability on core operations.